Macquarie Group’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-20,000
| Closed | -$345K | – | 1285 |
|
|
2025
Q3 | $345K | Hold |
20,000
| – | – | ﹤0.01% | 1450 |
|
|
2025
Q2 | $188K | Hold |
20,000
| – | – | ﹤0.01% | 1540 |
|
|
2025
Q1 | $142K | Hold |
20,000
| – | – | ﹤0.01% | 1546 |
|
|
2024
Q4 | $233K | Hold |
20,000
| – | – | ﹤0.01% | 1504 |
|
|
2024
Q3 | $411K | Hold |
20,000
| – | – | ﹤0.01% | 1498 |
|
|
2024
Q2 | $448K | Hold |
20,000
| – | – | ﹤0.01% | 1475 |
|
|
2024
Q1 | $550K | Hold |
20,000
| – | – | ﹤0.01% | 1436 |
|
|
2023
Q4 | $610K | Hold |
20,000
| – | – | ﹤0.01% | 1448 |
|
|
2023
Q3 | $632K | Hold |
20,000
| – | – | ﹤0.01% | 1413 |
|
|
2023
Q2 | $816K | Hold |
20,000
| – | – | ﹤0.01% | 1393 |
|
|
2023
Q1 | $745K | Hold |
20,000
| – | – | ﹤0.01% | 1413 |
|
|
2022
Q4 | $698K | Sell |
20,000
-479
| -2% | -$22.8K | ﹤0.01% | 1475 |
|
|
2022
Q3 | $1.19M | Sell |
20,479
-793
| -4% | -$49.2K | ﹤0.01% | 1382 |
|
|
2022
Q2 | $1.1M | Hold |
21,272
| – | – | ﹤0.01% | 1461 |
|
|
2022
Q1 | $1.54K | Hold |
21,272
| – | – | ﹤0.01% | 1442 |
|
|
2021
Q4 | $2.52M | Sell |
21,272
-287
| -1% | -$36K | ﹤0.01% | 1305 |
|
|
2021
Q3 | $2.89M | Buy |
21,559
+730
| +4% | +$111K | ﹤0.01% | 1258 |
|
|
2021
Q2 | $3.37M | Sell |
20,829
-528
| -2% | -$41.1K | ﹤0.01% | 1250 |
|
|
2021
Q1 | $1.71M | Sell |
21,357
-416
| -2% | -$27.9K | ﹤0.01% | 1249 |
|
|
2020
Q4 | $1.18M | Hold |
21,773
| – | – | ﹤0.01% | 1269 |
|
|
2020
Q3 | $433K | Hold |
21,773
| – | – | ﹤0.01% | 1432 |
|
|
2020
Q2 | $457K | Buy |
+21,773
| New | +$370K | ﹤0.01% | 1369 |
|
|
2019
Q1 | – | Sell |
-300
| Closed | -$4K | – | 1921 |
|
|
2018
Q4 | $4K | Buy |
300
+200
| +200% | +$3.72K | ﹤0.01% | 2137 |
|
|
2018
Q3 | $3K | Sell |
100
-3,600
| -97% | -$105K | ﹤0.01% | 2111 |
|
|
2018
Q2 | $101K | Buy |
+3,700
| New | +$89.6K | ﹤0.01% | 1841 |
|
Other funds holding NTLA
AIM
RP
